Disc Medicine Financial Statements
NASDAQ: IRONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
62.06+1.29 (+2.12%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Disc Medicine revenue and earnings
Disc Medicine reported a net loss of $212.2 million, compared with a loss of $109.4 million a year earlier. Diluted earnings per share came in at -$6.01.
Summary generated from market data by MetaCap's automated system. Methodology
Disc Medicine income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Operating Expenses | 236.02M | 129.72M | 91.13M | 47.48M | 30.93M | 34.04M |
| Research & Development | 170.64M | 96.67M | 69.26M | 33.44M | 25.17M | 28.17M |
| Selling, General & Admin | 65.38M | 33.05M | 21.86M | — | — | — |
| Operating Income | -236.02M | -129.72M | -91.13M | -47.48M | -30.93M | -34.04M |
| Interest Expense | 3.61M | 572.00K | 0 | — | 2.16M | 6.83M |
| Other Income (Expense) | 24.20M | 20.72M | 14.79M | 648.00K | -5.04M | — |
| Pretax Income | -211.82M | -109.00M | -76.33M | -46.83M | — | — |
| Income Tax | 361.00K | 355.00K | 99.00K | 0 | — | — |
| Net Income | -212.18M | -109.36M | -76.43M | -46.83M | -35.97M | -40.84M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -6.01 | -3.96 | -3.42 | -45.05 | -40.95 | -2.70 |
| EPS (Diluted) | -6.01 | -3.96 | -3.42 | -45.05 | -40.95 | -2.70 |
| Shares Outstanding (Basic) | 35.30M | 27.61M | 22.32M | 1.04M | 878.41K | 15.12M |
| Shares Outstanding (Diluted) | 35.30M | 27.61M | 22.32M | 1.04M | 878.41K | 15.12M |
| EBITDA | -235.74M | -129.56M | -91.03M | -47.39M | -30.90M | -33.72M |
This table shows 6 annual periods of Disc Medicine's income statement, from FY 2025 back to FY 2020, across 14 line items including operating expenses, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow IRON's reporting calendar. What is a income statement?